Sunshine Biopharma, Inc.
6100 Royalmount Avenue
Montreal
Quebec
H4P 2R2
Canada
Tel: 514-496-5197
Fax: 450-689-639
Website: http://sunshinebiopharma.com/
Email: info@sunshinebiopharma.com
119 articles about Sunshine Biopharma, Inc.
-
Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering
2/15/2024
Sunshine Biopharma, Inc. announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company of approximately $10.0 million, before deducting underwriting discounts and other estimated expenses payable by the Company.
-
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
2/13/2024
Sunshine Biopharma, Inc. today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company.
-
Sunshine Biopharma Moves Principal Office to New York City
12/4/2023
Sunshine Biopharma, Inc., a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals announced that it has moved its headquarters to New York City.
-
Sunshine Biopharma Reports 2023 Third Quarter Results: Revenues up Significantly Over Last Year Due to a Key Acquisition
11/13/2023
Sunshine Biopharma Inc. today announced that it has filed its quarterly report for the 2023 third quarter.
-
Sunshine Biopharma Receives 180-Day Extension To Achieve Nasdaq Minimum Bid Compliance
9/21/2023
Sunshine Biopharma Inc., a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals announced that it has received a 180-day extension, until March 18, 2024, to achieve compliance with the Nasdaq $1.00 minimum bid price rule.
-
Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%
8/11/2023
Sunshine Biopharma Inc., a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals announced that it has filed its quarterly report for the 2023 second quarter.
-
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement Priced At-the-Market
5/16/2023
Sunshine Biopharma Inc. closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.
-
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
5/12/2023
Sunshine Biopharma Inc. announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.
-
Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%
5/11/2023
Sunshine Biopharma Inc., a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals announced that it has filed its 2023 first quarter report.
-
Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update
4/5/2023
Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal year ended December 31, 2022 and recent highlights.
-
Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment
2/28/2023
Sunshine Biopharma Inc. today announced the signing of an exclusive worldwide license agreement (the “License Agreement”) with the University of Arizona.
-
Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound
2/10/2023
Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of a research agreement with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada.
-
Sunshine Biopharma Announces Share Repurchase Program
1/19/2023
Sunshine Biopharma Inc. today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company’s common stock.
-
Sunshine Biopharma’s Annual Letter to Shareholders - December 20, 2022
12/20/2022
Sunshine Biopharma Inc., a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals issued a letter to shareholders from Dr. Steve Slilaty, Chairman and CEO of the Company.
-
Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project
11/16/2022
Sunshine Biopharma Inc. today announced that it has entered into a collaboration agreement with one of North America’s leading lipid nanoparticle (“LNP”) companies.
-
Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue
10/20/2022
Sunshine Biopharma Inc. today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately.
-
Sunshine Biopharma Files Its Second Quarter Report With the SEC
8/4/2022
Sunshine Biopharma, Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has filed its 2022 second quarter report with the Securities and Exchange Commission.
-
Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona
7/28/2022
Sunshine Biopharma Inc. today announced that it has agreed to provide additional resources to the University of Arizona R. Ken Coit College of Pharmacy for the purposes of accelerating the development of novel PLpro inhibitors currently underway.
-
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private Placement Priced At-the-Market
4/28/2022
Sunshine Biopharma, Inc. closed its previously announced private placement pursuant to a securities purchase agreement entered into on April 25, 2022 with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.
-
Sunshine Biopharma, Inc. Announces Pricing of $19.5 Million Private Placement Priced At-the-Market
4/26/2022
Sunshine Biopharma, Inc. announced that it entered into a securities purchase agreement with certain institutional and accredited investors for aggregate gross proceeds of approximately $19.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.